Targets › EIF2B
1 program from 1 company in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.
Component of the eIF2 complex that functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form the 43S pre-initiation complex (43S PIC). Junction of the 60S ribosomal subunit to form the 80S initiation complex is preceded by hydrolysis of the GTP bound to eIF2 and release of an eIF2-GDP…. (UniProt, P20042)
Open in Phaseline: the race on EIF2B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of Soochow University | homoharringtonine Protein synthesis inhibitor | EIF2B | Phase 2 | Intermediate Risk Acute Myeloid Leukemia; Acute Myeloid Leukemia | Dec 2026 |
Intermediate Risk Acute Myeloid Leukemia (1) Acute Myeloid Leukemia (1)
small molecule (1)
The First Affiliated Hospital of Soochow University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.